Participated · Series B · Jun 2026

Triorb develops the TriOrb BASE, a ball-driven 360° omnidirectional mobility platform that uses three spheres and three motors at its base to achieve full-direction movement. The platform offers millimeter-level positioning and autonomous navigation via proprietary Visual SLAM and ROS2 modules and supports coordinated transport of multiple units. The standard model has a 300 kg payload capacity while a heavy-duty model carries up to 800 kg; the system can traverse 45 mm grooves, 10 mm steps, and gradients of approximately 9°. An optional battery provides about 3.5 hours of continuous operation. Target industries include automotive, semiconductors, steel manufacturing, warehousing and logistics, and construction, and a cited adoption example is Sugino Machine’s new mobile manipulator. The company has opened a Detroit base to support U.S. expansion.

Participated · Series B · Apr 2026

Restore Vision is developing optogenetics-based gene therapies, notably its lead program RV-001 which introduces a proprietary light-sensor protein called Chimera Rhodopsin into retinal interneurons via AAV intravitreal injection. The approach targets retinal diseases such as retinitis pigmentosa where photoreceptors have been lost. The company has completed first patient administration in a Phase I/II clinical trial of RV-001 at Keio University Hospital. Restore Vision plans to advance global clinical development of RV-001 and to pursue research and development of a second pipeline. Financially, the company has raised approximately ¥3.5 billion in equity to date and received about ¥2.1 billion in AMED grants, totaling roughly ¥5.8 billion in funding, with potential for an additional ¥4.5 billion through the AMED project.

Participated · Series A · Sep 2025

Founded in May 2022 and headquartered in Chiyoda, Tokyo, FerroptoCure is a drug-discovery startup focused on controlling ferroptosis to create novel cancer treatments. Its lead candidate, FC-004, is advancing toward overseas clinical trials, while additional pipelines are progressing through non-clinical studies. The company plans to use its newly raised funds to finance these trials, strengthen its team for the next development phase, and lay the groundwork for global expansion. FerroptoCure’s approach builds on academic research from Keio University and related national R&D programs. Although the company has not disclosed revenue or patient metrics, it has secured meaningful institutional backing to support its R&D roadmap. The management team, led by CEO Yuji Otsuki, counts investors with deep life-science expertise among its supporters, positioning the company to accelerate development of ferroptosis-based therapies beyond oncology into cardiovascular and neurodegenerative indications. Including its recent Series A and accompanying government grant, FerroptoCure has raised approximately ¥960 million (about $6.5 million) to date.

Participated · Series A · Jul 2025

FELIQS is a Fukuoka, Japan–based biotechnology company founded in 2019 that develops first-in-class small molecule therapeutics targeting oxidized lipids for rare pediatric retinal diseases. Its lead program, FLQ-101, is a once-daily oral or intravenous solution designed to enhance physiological retinal vascularization and protect against inflammation and abnormal neovascularization to prevent retinopathy of prematurity (ROP). The company received FDA Fast Track and Orphan Drug designations for FLQ-101 in 2024. FELIQS plans to initiate the Phase 1b/2 tROPhy-1 study in the United States in summer 2025. It completed a $9 million Series A to accelerate clinical development and expand its operational and clinical development teams. Proceeds will also be used to strengthen collaborative research initiatives in the U.S. and build a broader pipeline of targeted pediatric ophthalmology treatments.

Participated · Equity · Feb 2024

TopoLogic is a research-driven startup originating from the University of Tokyo that leverages topological materials to tackle computational and thermal challenges. The company aims to commercialize applications that visualize energy and enable energy savings by exploiting unusual electronic band structures. TopoLogic is developing a new MRAM chip called TL-RAM targeting low power consumption and fast write speeds to address rising data-center power use driven by AI. It is also developing a thermal flux sensor, TL-SENSING, which promises ultra-fast response and low cost for heat visualization with applications such as battery anomaly detection and thermal management. The recent fundraising announced provides capital to accelerate these two core projects and further industrial deployment of topological-materials technology.